Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

J&J Topamax Approved For Migraine Prevention In Twice-Daily Dose

This article was originally published in The Pink Sheet Daily

  • News
  • Elizabeth Walker

Executive Summary

The supplemental indication for topiramate clears FDA. The recommended twice-daily dose for migraine prevention may place Topamax at a disadvantage to Abbott’s once-daily dosing for Depakote ER.

You may also be interested in...



Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad

Rollout of Ortho-McNeil's disease awareness ad coincides with sales force launch meeting for the new indication. The ad directs patients to a toll-free phone number and a website.

Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad

Rollout of Ortho-McNeil's disease awareness ad coincides with sales force launch meeting for the new indication. The ad directs patients to a toll-free phone number and a website.

J&J Is Spitzer's Next Target: New York AG Opens Broad Off-Label Promotion Investigation

Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.
Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS060279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By